by Simon Rodwell | 1 February 2020 08:07
Melanoma Focus is pleased to share the Melanoma Patients Matter Report 2021, which has been published by the pharmaceutical company Bristol-Myers Squibb.
Less than a decade ago, treatment options for patients with advanced melanoma were limited, with chemotherapy the main treatment for many patients. In recent years, new treatments have become available for patients with advanced and metastatic melanoma – the first to be approved in several decades. The NHS has been relatively quick to adopt these, and now that there is a larger range of options available, it is important that all patients are provided with the information and support they need to make informed choices about which treatment would be best for them. The report is intended to explore how much this is happening in practice.
Bristol-Myers Squibb, Melanoma Focus, the British Association of Skin Cancer Specialist Nurses (BASCSN), Melanoma Action and Support Scotland (MASScot) and Melanoma
UK have come together to find out how patients are being involved in decisions about their care
This report summarises the results of a patient survey, which sought the views of a sample of patients with stage three or stage four melanoma
across the UK.
Informed by the survey findings and existing standards of care in cancer, this report makes a series of recommendations for ensuring advanced melanoma patients
are empowered with sufficient and appropriate information to be as involved as they want to be in all decisions about their treatment, care and support.
Further information can be found in the accompanying Talking About Melanoma Matters discussion guide by Bristol Myers Squibb.
Source URL: https://melanomafocus.com/information-portal/mpmr-2021/
Copyright ©2021 Melanoma Focus unless otherwise noted.